Validation of a naturally-occurring animal model for SARS-CoV-2 infection
Validation of a naturally-occurring animal model for SARS-CoV-2 infection
批准号:
10455312
负责人:
Craig Andrew Miller
金额:
$24.07万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-01 至 2023-06-30
关键词:
2019-nCoVACE2AcuteAnimal ModelBloodCD8-Positive T-LymphocytesCOVID-19CellsClinicalCommunicable DiseasesDisease ProgressionElementsFamily FelidaeFelis catusFlow CytometryGenetic DriftGoalsHumanImmuneImmune System DiseasesImmunoassayImmunologic FactorsImmunologicsInfectionInflammatoryInterleukin-1 betaInterleukin-6KineticsLesionLung diseasesOklahomaRNARespiratory CenterSARS-CoV-2 infectionTNF geneTissuesValidationViral AntigensVirusVirus Replicationacute infectioncytokinedigitaleffective therapyhuman diseaseimmune functionimmunoregulationin vivonasal swabnovelreceptorrespiratorysevere COVID-19translational studyvaccine candidateviral fitness
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The overall objective of this project is to validate mechanisms of viral fitness and immunopathogenesis during SARS-CoV-2
infection in domestic cats to establish baselines for downstream translational studies. Major goals (specific aims) for this
project are as follows:
Aim 1. Evaluate in vivo infection kinetics and viral fitness of SARS-CoV-2 in the domestic cat. We will use droplet digital PCR
(ddPCR) to quantify absolute copy numbers of SARS-CoV-2 RNA in blood, nasal swabs, and respiratory tissues in order to
characterize viral replication kinetics during acute infection in domestic cats, and compare these changes with co-expression of
viral antigen and ACE2 receptors in respiratory tissues (IHC). We will also use virus amplicon sequencing assembly to evaluate
the potential for genetic divergence in the feline host (i.e. does the virus evolve during infection in domestic cats).
Hypotheses: SARS-CoV-2 infects ACE2-expressing feline respiratory cells, resulting in progressive replication of genetically
conserved virus elements and lesions analogous to human COVID-19
Aim 2. Identify key factors of immune dysfunction contributing to COVID-19 disease progression. We will use scRNASeq, flow
cytometry, and multiplex immunoassays to define shifts in the immune profile during acute SARS-CoV-2 infection. We will
compare changes in immunological parameters with viral replication kinetics (Aim 1) and clinical disease progression in order
to (i) define how perturbations of immune function impact clinical disease progression and (ii) identify novel
immunomodulatory targets to guide more effective therapies or vaccine candidates.
Hypothesis: Progression of severe COVID-19 in cats is analogous to human disease and correlated with (i) CD4+ and CD8+ T
cell deficiencies and (ii) pro-inflammatory cytokine expression (IL-6, IL-1β, TNFα,)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位:
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
-
批准号:32302080
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:宋田源
-
依托单位:
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
-
批准号:82305216
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:姚骏凯
-
依托单位:
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
-
批准号:82305171
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴永灿
-
依托单位: